Matto degeneration (NAMD) related to the new age is still the main reason for the loss of vision loss of the elderly, and the world has affected millions. Imagine a world that aims to protect our vision is the best in the secondary level, or it will lose its effectiveness over time. This is the reality of many struggles with NAMD, because many patients show incomplete reactions or resist the standard therapy over time. NAMD’s ruthless progress, coupled with the limitations of the current treatment, emphasizes the urgent needs corresponding to the new method of such weakness. However, as the researchers discovered a new strategy to solve this problem directly, it provided new ways to protect vision and improve the quality of life. Hope would become hope.
The latest research by Baylor Medical College’s Dr. Yingbin Fu team discussed the innovative strategy to overcome this resistance. Their discovery summary in the peer review journal “Biomolecules”.
The main method for treating NAMD is to inhibit vascular endothelial growth factor (VEGF), which is a key factor that promotes the growth characteristics of the disease abnormal blood vessels. However, despite the treatment, as many as 50 % of patients still show persistent diseases. This potential mechanism of resistance has not fully understood, but recent research shows that small arterial vessels of the newborn vascular formation (CNV) are important contributors. This type of new vascular formation involves large therapy blood vessels and vascular rings with low response to VEGF inhibitory.
“Macrophages Play a Key Role in Anti-Vegf Resistance by Contributing to Neovascular Remodeling,” PROFESSOR Fu Explained, “BeCAUSE Inflammatory Signaling OC Curred on Lipid-Rich Microdomains of Macrophage Membrane, One Effective Approach is to Enhance CHOLELOLELOLROVAL FROM MACROPHAGES with with the TEIN AI Combining protein (AIBP) and cholesterol suffering from body loading AI.
It is difficult to treat anti -VEGF resistance, because VEGF raises macrophages to the diseased part of inflammation, and macrophages secrete other VEGF and other vascular promotional factors, which has a vicious circle. To solve this problem, Professor FU team develops a combination therapy by developing VEGF and macrophages. They show a encouraging result in the animal model, that is, the current combination of anti -VEGF therapy and AIBP and lipoprotein AI provides an effective treatment strategy that can improve the resistance to VEGF resistance in AMD.
Despite these progress, the study acknowledged that further research needs to be verified in the clinical environment. NAMD’s complexity is affected by factors such as age, genetic susceptibility, and environmental impact. Multiple treatment methods need to be used to achieve the best management of AMD patients. The combination therapy developed by the FU team is an important step towards this goal.
All in all, the research of Dr. FU and his team emphasized the demand for innovative combination therapy for challenges against VEGF resistance in NAMD. Through targeting vascular production and inflammation, these strategies are expected to improve the long -term efficacy of treatment and reduce the burden of vision loss of the elderly. These discoveries paved the way for future clinical trials to develop more comprehensive and effective therapies for this weakened situation.
Journal reference
Fu, Y., ZHANG, Z., Webster, KA, & Paulus, YM (2024). By targeting the formation of newborn vascular formation of the arterial vein, the treatment strategy of anti -VEGF resistance in the degeneration of neonatal vascular degeneration. Biomolecular, 14 (252). DOI:
